Innovating Cancer Care
Cutting-Edge Solutions for Oncology Advancements
Transforming the landscape of cancer treatment, our platform empowers healthcare professionals with innovative AI solutions. Our advanced technology integrates seamlessly into your practice, offering personalized therapy recommendations and comprehensive insights. By bridging science and technology, we aim to elevate patient care and enhance clinical outcomes.
Elevating Care
The Exacta-Ai
Engine
Discover how our platform employs cutting-edge AI and big data analytics to support clinical decision-making. Our mission is to improve therapeutic accuracy and outcomes for patients facing cancer. By enabling a more informed approach to oncology, we are setting new standards in personalized medicine.
Analytical Framework
- Lab data integration
- Multi-layer analysis framework
- Drug scoring algorithm
- Drug selection and combination optimization
- Toxicity evaluation (including drug-drug interactions and pharmacogenomics)
- Quality control
Clinical Framework
- Review of published case studies and clinical trial data
- Review of standard of care options
- Decision drive
- Quality control
- Evaluation of limitations
- Patient history
AI + NI + EI = Exacta AI
The Three Pillars of Intelligence Cancer Care
Artificial Intelligence (AI)
Exacta-AI processes vast medical data, analyzing genomics, drug responses, and treatment resistance. It provides oncologists with evidence-based, personalized therapy options, helping patients receive the most effective treatment for their specific cancer type.
Natural Intelligence (NI)
Exacta-NI combines human expertise, clinical experience, and medical intuition to interpret complex cancer data. It ensures that AI-driven therapy recommendations are reviewed, validated, and personalized by oncologists for optimal patient outcomes.
Emotional Intelligence (EI)
Exacta-EI focuses on compassionate cancer care, offering lifelong support beyond treatment. By monitoring Molecular Residual Disease (MRD) and patient well-being, it ensures continuous care, reducing uncertainty for both patients and oncologists.
Comprehensive Data Integration
Exacta-Ai seamlessly integrates genomic, proteomic, and clinical data to provide a comprehensive, real-time view of each patient’s cancer. This enables precise, evidence-based therapy recommendations that evolve with the disease, ensuring personalized and effective treatment strategies.
Next-Generation Sequencing
Decoding the genetic blueprint for targeted / immuno therapy.
Protein Expression Profiles
Analyzing proteomic signals to identify actionable markers.
Chemosensitivity Testing
Evaluating drug efficacy to personalize treatment strategies.
Transcriptomic Analysis
Incorporating transcriptome data for strengthening genomic, proteomic, and clinical insights for a contextually complete picture.
Pharmacogenomics
Pharmacogenomics based mitigation strategy
to avoid potentially
high-risk therapies.
Clinical Parameters
Contextualizing data with patient-specific clinical insights such as co-morbidities, accumulated toxicities and previously failed treatments.
Resistance Mechanism Identification
Identifying causes of resistance for adaptive mitigations.
Exacta-Ai
Drug Selection
CE: Capillary Electrophoresis; cfDNA: cell free DNA; CNAs: copy number alterations; CRSP: Chemoresistance / Sensitivity Profiling; CTCs: circulating tumor(associated) cells; Fus: Fusions (Rearrangements); gDNA: genomic DNA; HR: hormone receptor; ICC: Immunocytochemistry; IHC: immunohistochemistry; InDels: Insertions and Deletions; MLPA: multi-ligand probe analysis; MMR: mismatch repair; MSI: microsatellite instability; NGS: Next Generation Sequencing; PDL1: programmed death ligand-1; PGx: pharmacogenomics; SNPs: single nucleotide polymorphisms; SNVs: single nucleotide variants; TDCs: tumor derived cells; TMB: tumor mutation burden; ttDNA: tumor tissue DNA; ttRNA: tumor tissue RNA;
Know More About ExactaTM
Exacta360™ is a validated and advanced AI-driven test designed for patients with advanced or difficult-to-treat cancers, especially those unresponsive to standard therapies. By conducting comprehensive, multi-analyte tumor profiling—including analyses of RNA, DNA, circulating tumor cells (CTCs), proteomics, and live cell chemo-response—Exacta360™ provides detailed insights into tumor mechanisms. This in-depth analysis informs the selection of personalized anti-cancer treatment regimens, helping oncologists identify the most effective therapies tailored to each patient’s unique cancer profile.
Validated and Comprehensive
ExactaTM is a clinically validated test designed to guide treatment decisions for patients with advanced or difficult-to-treat cancers.
Multi-Analyte Tumor Profiling
ExactaTM analyzes DNA, RNA, circulating tumor cells (CTCs), proteomics, and live cell chemo-response to provide a complete tumor assessment.
Personalized Therapy Selection
ExactaTM helps oncologists identify the most effective anti-cancer treatments tailored to each patient’s unique tumor biology.
For Patients Who Need More Options
ExactaTM ideal for those who have not responded to standard therapies, offering new possibilities for treatment strategies.